Appointment of Non-Executive Director

(AIM:PRM) Proteome Sciences plc has announced the appointment of Helen Spice FCA as an independent non-executive director of the Company, effective immediately. Helen Spice previously had a successful accountancy career at KPMG, where she served as CFO of KPMG International from 2008 to 2015. She is currently a non-executive director at Barts Health NHS Trust and recently retired from Great Western Hospitals NHS Foundation Trust, where she was Chair of the Audit, Risk and Assurance Committee. Additional current and past directorships held by Helen Spice in the last five years include Make-a-Wish Foundation UK and Mental Health and Employment Partnership Limited. Helen Spice does not currently hold any ordinary shares, options, or warrants in Proteome Sciences plc. The Company states that there are no further disclosures required in accordance with AIM Rule 17 or Schedule Two, paragraph (g) of the AIM Rules for Companies. Proteome Sciences plc is a specialist provider of contract proteomics services for drug discovery, development, and biomarker identification. The Company employs proprietary workflows, including SysQuant® and TMT®MS2, for the analysis of tissues, cells, and body fluids. The TMTcalibrator™ platform provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift is used to reveal drug selectivity for protein binding in the sample proteome. Targeted assay development using mass spectrometry is offered for high sensitivity, interference-free biomarker analyses where standard ELISA assays are not available. The Company's LEI is 213800Q62ICXANKU2986.

Further GCLP Chemoproteomics contract secured

(AIM:PRM) Proteome Sciences plc has secured a significant clinical contract for its GCLP-compliant chemoproteomics platform. This is the third contract related to the same protein for ongoing global phase 1 and phase 2 clinical trials. The project will be conducted at the company's laboratories in Frankfurt, Germany. Sample shipments for the project are expected to begin later this year. The majority of the work is anticipated to be completed in 2027. The company states that this contract highlights continued demand from major biopharma clients in the US and Europe for GCLP-grade protein assays using mass spectrometry-based techniques. Richard Dennis, Chief Commercial Officer, commented that there is an increasing requirement for these approaches as more complex drugs enter clinical trials and future biomanufacturing. Christopher Pearce is named as Executive Chairman. The company’s SysQuant® and TMT®MS2 methods, along with TMTcalibrator™, provide access to over 8,500 circulating plasma proteins for biomarker discovery. Chemoproteomics using Solvent Shift is used to reveal drug selectivity for protein binding. Targeted assay development with mass spectrometry is used for high sensitivity, interference-free biomarker analyses where standard ELISA assays are not available. The company’s LEI is 213800Q62ICXANKU2986.